Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Immobilized Biotinylated Human CD39 (R138A, M139A, E142K) Protein, His,Avitag (Cat. No. CD9-H82E8) at 1 μg/mL (100 μL/well)on streptavidin precoated (Cat. No. STN-N5116) (0.5 μg/well) plate can bind Anti-CD39 Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
The purity of Cynomolgus CD39 Protein, His Tag (Cat. No. CD9-C5PH3) is more than 85% and the molecular weight of this protein is around 65-85 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| ES-002 | ES-002 | Phase 1 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Solid tumours; Neoplasms | Details |
| ES-002023(Elpiscience Biopharma) | Phase 1 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Solid tumours | Details | |
| PUR-001 | PUR-001 | Phase 1 Clinical | Purinomia Biotech Inc | Solid tumours; Neoplasms | Details |
| JS-019 | JS-019 | Phase 1 Clinical | Beijing Enrini Biotechnology Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
| IPH-5201 | IPH-5201 | Phase 2 Clinical | Inserm, Orega Biotech | Solid tumours; Neoplasms; Lung Neoplasms | Details |
| ES-014 | ES-014 | Phase 1 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Solid tumours; Neoplasms | Details |
| SRF-617 | SRF-617 | Phase 2 Clinical | Surface Oncology Inc | Solid tumours; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| TTX-030 | TTX-030 | Phase 1 Clinical | Tizona Therapeutics Inc, Abbvie Inc | Solid tumours; Lymphoma | Details |
This web search service is supported by Google Inc.
A-Z
